Article

Quantel Medical debuts IPL system for dry eye treatment

According to the company, its C.STIM IPL system is based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical's C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical's C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical today announced the launch of its C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Dry eye is a huge public health problem affecting more than 700 million people in the word and it is the most common pathology in ophthalmic visits. Dry eye treatment is now a key question in many specialties like glaucoma, refractive & cataract surgeries, contact lenses and others.

The company pointed out in a news release that the IPL system treats the root causes of dry eyes: Meibomian gland dysfunction, inflammation, and Demodex, to stop the vicious cycle of dry eye.

According to Delphine Southon, dry eye product manager, C.STIM, the platform offers clinical efficacy and patient comfort.

C.STIM has been designed with the aim of combining cutting-edge technology with a sleek, robust and ergonomic design. The device integrates the best technological features to guarantee efficacy, safety, ergonomics and to offer a “plug and play” product easy delegable.

“Drawing on Quantel Medical’s years of experience in intense pulsed light in dermatology, we have now developed an IPL device exclusively for use in ophthalmology designed and manufactured by the Lumibird Medical Group, said said Jean-Marc Gendre, CEO of Lumibird Medical.

Gendre said the product will offer a therapeutic solution to ophthalmologists to treat patients with dry eye disease.

According to the news release, Quantel Medical provides ophthalmologists with therapeutic laser solutions to treat the four main causes of blindness: glaucoma, cataracts, diabetic retinopathy and macular degeneration.

Lumibird Medical is the medical holding of the Lumibird Group, a company invoolvled in the development of solid-state lasers for scientific and industrial use. It comprises Quantel Medical (France and Polska) and Ellex (Australia, Japan and United States), since July 2020, along with Optotek Medical in Slovenia and Lumibird Medical Nordics (Sweden, Finland and Norway)

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
© 2025 MJH Life Sciences

All rights reserved.